Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Covance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Covance

Early and late-stage FY revenues up 11% and 7%, respectively

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Covance

4Q Revenues: $582.4 million (+8%)

4Q Earnings: $21.1 million (-26%)

FY Revenues: $2.1 billion (+9%)

FY Earnings: $132.2 million (+94%)

Comments: Early Development revenues were $234.5 million in the quarter (+6%) and $930.6 million for the year (+11%). Revenue growth in the quarter was driven by results from the company’s new Alnwick, UK and Porcheville, France sites and clinical pharmacology, partially offset by a $5.7 million sequential decline due to lower demand in research products and European toxicology services, as well as a $2.3 million foreign exchange impact.Late-Stage Development revenues were $298.0 million in the quarter (+10%) and $1.2 billion for the year (+7%).The company recorded a $12.1 million impairment charge in the quarter for an equity investment in a supplier of research products. Backlog at December 31, 2011 was $6.1 billion compared to $6.2 billion in 2010. Foreign exchange negatively impacted backlog growth by $75 million. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics